IMUC

ImmunoCellular Therapeutics, Ltd. [IMUC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IMUC Stock Summary

In the News

06:00 28 Mar 2024 IMUC

ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market

LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021.

IMUC Financial details

Company Rating
Buy
Market Cap
31.02M
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
13 Mar 2024
P/E
-0.09
Forward P/E
-
PEG
-
P/S
-
P/B
0.36
P/C
-
P/FCF
-2.72
Quick Ratio
2.81
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-17.86%
SMA50
-42.5%
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-264%
ROE
-344%
ROC
-4.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
113.27M
Shs Float
112.95M
-
-
-
-
Target Price
-
52W Range
0.151-0.4
52W High
-
52W Low
-
RSI
40.27
Rel Volume
18.02
Avg Volume
2.12K
Volume
38.12K
Perf Week
-17.19%
Perf Month
-36.9%
Perf Quarter
-26.21%
Perf Half Y
-34.64%
-
-
-
-
Beta
1.377
-
-
Volatility
0.03%, 0.03%
Prev Close
-20.43%
Price
0.183
Change
-8.5%

IMUC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2016-12-312017-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-83.6-4.42-0.03-0.050
Operating cash flow per share
-70.97-3.98-0.03-0.020
Free cash flow per share
-70.99-3.98-0.03-0.020
Cash per share
40.861.580.010.010
Book value per share
21.911.110-0.010
Tangible book value per share
21.911.110-0.010
Share holders equity per share
21.911.110-0.010
Interest debt per share
4.690.2100.020
Market cap
5.74M13.24M21.19M47.57M92.85K
Enterprise value
-5.7M6.61M20.92M48.9M92.85K
P/E ratio
-0.25-0.72-14.58-9.240
Price to sales ratio
00000
POCF ratio
-0.29-0.79-17.13-20.630
PFCF ratio
-0.29-0.79-17.13-20.630
P/B Ratio
0.942.85163.5-29.440
PTB ratio
0.942.85163.5-29.440
EV to sales
00000
Enterprise value over EBITDA
0.23-0.31-14.4-18.710
EV to operating cash flow
0.29-0.4-16.91-21.20
EV to free cash flow
0.29-0.4-16.91-21.20
Earnings yield
-4.08-1.4-0.07-0.110
Free cash flow yield
-3.46-1.26-0.06-0.050
Debt to equity
000-1.740
Debt to assets
0001.690
Net debt to EBITDA
0.470.310.18-0.510
Current ratio
4.142.971.923.580
Interest coverage
-18.38-23.960-308.850
Income quality
0.91.160.850.450
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.050000
Stock based compensation to revenue
00000
Graham number
202.9910.50.050.120
ROIC
-4.17-5.89-11.2-2.180
Return on tangible assets
-1.39-2.64-5.45-3.090
Graham Net
4.541.020-0.020
Working capital
10.18M4.65M125.85K1.2M0
Tangible asset value
6.13M4.65M129.58K-1.62M0
Net current asset value
2.66M4.65M125.85K-1.62M0
Invested capital
000-1.740
Average receivables
00000
Average payables
1.25M1.56M000
Average inventory
593.09K593.09K000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-3.82-3.98-11.213.190
Capex per share
-0.010000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.010000
Operating cash flow per share
00000
Free cash flow per share
00000
Cash per share
0.010000
Book value per share
-0.050000
Tangible book value per share
-0.050000
Share holders equity per share
-0.050000
Interest debt per share
0.040000
Market cap
64.09K0000
Enterprise value
63.54K0000
P/E ratio
-210000
Price to sales ratio
00000
POCF ratio
00000
PFCF ratio
00000
P/B Ratio
-17.190000
PTB ratio
-17.190000
EV to sales
00000
Enterprise value over EBITDA
-783.320000
EV to operating cash flow
00000
EV to free cash flow
00000
Earnings yield
-0.010000
Free cash flow yield
00000
Debt to equity
-0.820000
Debt to assets
4.270000
Net debt to EBITDA
6.790000
Current ratio
0.970000
Interest coverage
00000
Income quality
00000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
0.10000
ROIC
0.90000
Return on tangible assets
-1.070000
Graham Net
-0.050000
Working capital
-20.250000
Tangible asset value
-3.73K0000
Net current asset value
-3.73K0000
Invested capital
-0.820000
Average receivables
00000
Average payables
00000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.20000
Capex per share
00000

IMUC Frequently Asked Questions

What is ImmunoCellular Therapeutics, Ltd. stock symbol ?

ImmunoCellular Therapeutics, Ltd. is a US stock , located in Montvale of Nj and trading under the symbol IMUC

What is ImmunoCellular Therapeutics, Ltd. stock quote today ?

ImmunoCellular Therapeutics, Ltd. stock price is $0.183 today.

Is ImmunoCellular Therapeutics, Ltd. stock public?

Yes, ImmunoCellular Therapeutics, Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Same Price Range
Similar Market Cap